Psoriasis trials in Germany

In Germany 25 Also abroad 274

25 trials · From ClinicalTrials.gov and EU CTIS (euclinicaltrials.eu), checked 10 November 2026. Ask the study team whether a trial fits you.

Phase 4Taking people
An open-label, multi-center protocol for patients who have completed a previous Novartis sponsored Secukinumab study and are judged by the investigator to benefit from continued Secukinumab treatment
Where
Berlin
People
339 worldwide
Run by
Novartis Pharma AG
See details and how to joinNCT04638647 · EU 2023-504417-67-00
Phase 1Taking people
A Study to Learn if Bimekizumab Given in Different Ways is Safe and Moves Similarly Throughout the Body Over Time in Adults
Where
Berlin, Hamburg, Ratingen, Wetzlar
Age
18 years and over
People
392 worldwide
Run by
UCB Biopharma SRL
See details and how to joinNCT07290036
Phase 3Taking people
A Long-term Extension (LTE) Study of Guselkumab in Pediatric Participants
Where
Hamburg, Sankt Augustin
Age
3 years to 64 years
People
196 worldwide
Run by
Janssen Research & Development, LLC
See details and how to joinNCT06663332 · EU 2023-509560-16-00
No phaseTaking people
Glucocorticoid-induced Osteoporosis in Patients With Chronic Inflammatory Rheumatic Diseases or Psoriasis
Where
Berlin
Age
18 years and over
People
10,000
Run by
Prof Dr Frank Buttgereit
See details and how to joinNCT02719314
Phase 3Taking people
Long-Term Safety Study of Deucravacitinib Versus Ustekinumab in Participants With Psoriasis (PRAGMATYK)
Where
Bad Bentheim, Berlin, Blankenfelde-Mahlow, Bramsche, Dresden, Erlangen, Frankfurt Am Main, Friedrichshafen, Halle, Hamburg, Heidelberg, Kiel, Langenau, Mainz, Memmingen, Merzig, Muenster, Quedlinburg, Tuebingen, Witten, Wuerzburg
Age
40 years and over
People
3,040 worldwide
Run by
Bristol-Myers Squibb
See details and how to joinNCT07116967 · EU 2023-503766-24-00
No phaseTaking people
PsoBest - The German Psoriasis Registry
Where
Hamburg
Age
18 years and over
People
3,500
Run by
Universitätsklinikum Hamburg-Eppendorf
See details and how to joinNCT01848028
Phase 3Taking people
A Study to Evaluate the Efficacy, Safety, and Drug Levels of Deucravacitinib (BMS-986165) in Adolescent Participants With Moderate to Severe Plaque Psoriasis
Where
Berlin, Dresden, Erlangen, Mainz, Muenster
Age
12 years to 17 years
People
366 worldwide
Run by
Bristol-Myers Squibb
See details and how to joinNCT06979453 · EU 2023-506296-97-00
Phase 3Taking people
A Study to Evaluate the Drug Levels, Efficacy and Safety of Deucravacitinib in Children and Adolescent Participants With Moderate to Severe Plaque Psoriasis
Where
Berlin, Dresden, Hamburg, Mainz, Muenster
Age
4 years to 18 years
People
153 worldwide
Run by
Bristol-Myers Squibb
See details and how to joinNCT04772079 · EU 2022-502519-13-00
Phase 2Taking people
An Open-Label Extension Study of ORKA-001 in Participants With Plaque Psoriasis
Where
Bad Bentheim, Frankfurt Am Main, Heidelberg, Kiel
Age
18 years and over
People
240 worldwide
Run by
Oruka Therapeutics, Inc.
See details and how to joinNCT07449702 · EU 2026-526898-42-00
Phase 3Taking people
A Study of Zasocitinib in Adults With Psoriatic Arthritis Who Have Not Taken Biologic Medicines
Where
Bad Bentheim, Bad Doberan, Berlin, Dresden, Hamburg, Leipzig, Munich, Ratingen
Age
18 years and over
People
1,088 worldwide
Run by
Takeda
See details and how to joinNCT06671483 · EU 2024-513111-27-00
No phaseTaking people
Study to Assess Change in Quality of Life of Risankizumab Treatment in Adult Participants With Moderate-to-Severe Plaque Psoriasis
Where
Dortmund, Friedrichshafen, Hamburg, Heilbad Heiligenstadt, Kulmbach, Leipzig, Mainz, Mölln, Munich, Potsdam, Schwelm
Age
18 years and over
People
700 worldwide
Run by
AbbVie
See details and how to joinNCT07039110
Phase 1Taking people
A Study to Assess the Concentration of Bimekizumab in Mature Breast Milk From Mothers Receiving Treatment With Bimzelx® (Bimekizumab)
Where
Freiburg im Breisgau, Herne
Age
18 years and over
People
20 worldwide
Run by
UCB Biopharma SRL
See details and how to joinNCT06888193 · EU 2024-518689-29-00
Phase 3Taking people
A Long-Term Study of Zasocitinib in Children and Teenagers With Plaque Psoriasis
Where
Bad Bentheim, Bonn, Cologne, Frankfurt Am Main, Mainz, Muenster
Age
4 years to 17 years
People
110 worldwide
Run by
Takeda
See details and how to joinNCT07250802 · EU 2025-522567-15-00
Phase 3Taking people
Continuation Study of Zasocitinib in Adults With Psoriatic Arthritis
Where
Bad Bentheim, Bad Doberan, Berlin, Dresden, Hamburg, Herne, Leipzig, Munich, Ratingen
Age
18 years and over
People
1,182 worldwide
Run by
Takeda
See details and how to joinNCT07286058 · EU 2025-522586-30-00
Phase 3Taking people
A Study to Assess Adverse Events, Change in Disease Activity, and How the Drug Moves Through the Body in Children With Juvenile Psoriatic Arthritis (jPsA) Receiving Subcutaneously Injected Risankizumab or Adalimumab
Where
Berlin, Hamburg, Sankt Augustin
Age
5 years to 17 years
People
40 worldwide
Run by
AbbVie
See details and how to joinNCT06100744 · EU 2023-506026-36-00
No phaseTaking people
Determinants of Chronic Inflammatory Skin Disease Trajectories
Where
Kiel
Age
0 years to 80 years
People
1,000
Run by
University Hospital Schleswig-Holstein
See details and how to joinNCT05928169
Phase 3Taking people
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis
Where
Berlin, Bramsche, Dresden, Duesseldorf, Hamburg, Kiel, Langenau, Leipzig, Lübeck, Mannheim, Munich, Potsdam, Rostock
Age
18 years and over
People
320 worldwide
Run by
Janssen - Cilag International
See details and how to join2023-505121-14-00 · EU 2023-505121-14-00
Phase 4Taking people
Safety and immunologic response of SHIngrix VAccination in patients suffering from Psoriasis or Psoriatic arthritis
Where
Bad Bentheim, Bonn, Frankfurt Am Main, Freiburg im Breisgau, Hamburg, Hanover, Marburg, Merzig, Muenster, Munich, Straubing, Wetzlar, Wuppertal
Age
18 years and over
People
336
Run by
Justus-Liebig-Universitaet Giessen
See details and how to join2024-512881-32-00 · EU 2024-512881-32-00
No phaseTaking people
An Ex-US Study to Assess Treatment Persistence With Risankizumab in Adult Participants With Psoriatic Arthritis
Where
Altenburg, Amberg, Berlin, Braunschweig, Frankfurt am Main, Greifswald, Halle, Hanover, Hohen Neuendorf, Kaiserslautern, Kassel, Lübeck, Magdeburg, Planegg, Püttlingen, Ratingen, Rendsburg, Templin, Trier, Wetzlar, Wuppertal
Age
18 years to 75 years
People
1,200 worldwide
Run by
AbbVie
See details and how to joinNCT06764693
No phaseTaking people
Clinical Assessment for Rheumatologic Disease - Research and Advancement in Safety and Efficacy
Where
Bonn
Age
18 years and over
People
120
Run by
University of Bonn
See details and how to joinNCT07150000
No phaseTaking people
Molecular Inflammation Board at the Center for Personalized Medicine
Where
Tübingen
Age
18 years and over
People
3,000
Run by
University Hospital Tuebingen
See details and how to joinNCT07132333
No phaseTaking people
Molecular Signatures in Inflammatory Skin Disease
Where
Kiel
People
300
Run by
Prof. Dr. Stephan Weidinger
See details and how to joinNCT03358693
No phaseTaking people
Disease Trajectories and Anti-cytokine Response Signatures in Atopic Dermatitis and Psoriasis
Where
Kiel
Age
0 years to 100 years
People
1,000
Run by
University Hospital Schleswig-Holstein
See details and how to joinNCT03361215
No phaseTaking people
AYLo - AutoimmunitY and Loss of y
Where
Bonn
Age
50 years and over
People
500
Run by
University of Bonn
See details and how to joinNCT06696027
No phaseTaking people
International Rare And Severe Psoriasis Expert Network
Where
München
Age
6 months and over
People
180 worldwide
Run by
University Hospital, Basel, Switzerland
See details and how to joinNCT04359394